Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells

Venetoclax is an effective treatment for certain blood cancers, such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). However, most patients relapse while on venetoclax and further treatment options are limited. Combining venetoclax with immunotherapies is an attractive approa...

Descripción completa

Detalles Bibliográficos
Autores principales: Teh, Charis E., Peng, Hongke, Luo, Meng-Xiao, Tan, Tania, Trussart, Marie, Howson, Lauren J., Chua, Chong Chyn, Muttiah, Christine, Brown, Fiona, Ritchie, Matthew E., Wei, Andrew H., Roberts, Andrew W., Bryant, Vanessa L., Anderson, Mary Ann, Lindeman, Geoffrey J., Huang, David C. S., Thijssen, Rachel, Gray, Daniel H. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275705/
https://www.ncbi.nlm.nih.gov/pubmed/36521105
http://dx.doi.org/10.1182/bloodadvances.2022008221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275705/
https://www.ncbi.nlm.nih.gov/pubmed/36521105
http://dx.doi.org/10.1182/bloodadvances.2022008221

Ejemplares similares